SCHEDULE 13G/A 0001633313 XXXXXXXX LIVE 1 Ordinary shares, nominal value 0.002 GBP per share 12/31/2025 0001847903 Centessa Pharmaceuticals plc 152309100 3rd Floor, 1 Ashley Road, Altrincham CHESHIRE X0 WA14 2DT Rule 13d-1(b) Avoro Capital Advisors LLC b DE 14555555.00 0.00 14555555.00 0.00 14555555.00 N 9.97 IA OO Represented by 14,555,555 ADSs (as defined in Item 2(a)). Behzad Aghazadeh b X1 14555555.00 0.00 14555555.00 0.00 14555555.00 N 9.97 HC IN Represented by 14,555,555 ADSs. Centessa Pharmaceuticals plc 3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT, United Kingdom This statement is filed by: (i) Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro"), which provides investment advisory and management services and has acquired ordinary shares, nominal value GBP 0.002 per share ("Ordinary Shares") of Centessa Pharmaceuticals PLC, a public limited liability company incorporated under the laws of England and Wales (the "Company") underlying ADSs (as defined below), solely for investment purposes on behalf of Avoro Life Sciences Fund LLC, a Delaware limited liability company, and (ii) Behzad Aghazadeh ("Dr. Aghazadeh," and together with Avoro, the "Reporting Persons"), who serves as the portfolio manager and controlling person of Avoro. The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 152309100 has been assigned to the American Depositary Shares ("ADSs") of the Company, which are quoted on the Nasdaq Global Select Market under the symbol "CNTA." Each ADS represents one Ordinary Share. The address of the business office of each of the Reporting Persons is 110 Greene Street, Suite 800, New York, NY 10012. Avoro is a Delaware limited liability company. Dr. Aghazadeh is a United States citizen. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 146,049,056 shares of Common Stock outstanding, as reported in the Company's Prospectus Supplement filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on November 13, 2025, after giving effect to the completion of theoffering described therein. 9.97% The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Y N See Item 2(a). Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Avoro Capital Advisors LLC /s/ Scott Epstein 02/17/2026 Behzad Aghazadeh /s/ Behzad Aghazadeh 02/17/2026